Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Clopidogrel Bisulfate
Generic Name
Clopidogrel Bisulfate
Active Ingredient
ClopidogrelCategory
P2Y12 Platelet Inhibitor [EPC]
Salt Form
Bisulfate
Variants
19
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 75 mg/1 | TABLET, FILM COATED | ORAL | 68788-7700 |
| 300 mg/1 | TABLET, FILM COATED | ORAL | 77771-121 |
| 75 mg/1 | TABLET, FILM COATED | ORAL |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Clopidogrel Bisulfate, you must consult a qualified healthcare professional.
| 300 mg/1 | TABLET, FILM COATED | ORAL | 43598-122 |
| 300 mg/1 | TABLET, FILM COATED | ORAL | 63739-178 |
| 75 mg/1 | TABLET, FILM COATED | ORAL | 43598-121 |
| 75 mg/1 | TABLET, FILM COATED | ORAL | 50228-124 |
| 75 mg/1 | TABLET, FILM COATED | ORAL | 63187-639 |
| 75 mg/1 | TABLET, FILM COATED | ORAL | 77771-124 |
| 300 mg/1 | TABLET, FILM COATED | ORAL | 50228-121 |
| 75 mg/1 | TABLET, FILM COATED | ORAL | 82009-182 |
| 75 mg/1 | TABLET, FILM COATED | ORAL | 47335-894 |
+ 7 more variants
Detailed information about Clopidogrel Bisulfate
Clopidogrel is a potent P2Y12 platelet inhibitor used to reduce the risk of heart attack and stroke in patients with cardiovascular disease. It works by preventing platelets from clumping together to form dangerous blood clots.
The dosage of clopidogrel is highly standardized but may vary based on the specific condition being treated. For most chronic conditions, such as the prevention of stroke or the management of peripheral arterial disease, the standard dose is 75 mg taken once daily.
In the context of Acute Coronary Syndrome (ACS), healthcare providers typically initiate treatment with a single 300 mg to 600 mg loading dose. This high initial dose is necessary because clopidogrel is a prodrug; a single 75 mg dose can take several days to reach a steady state of platelet inhibition, whereas a loading dose can achieve significant effects within 2 to 6 hours. Following the loading dose, the patient transitions to the 75 mg daily maintenance dose. When used for ACS or after a stent placement, clopidogrel is almost always taken alongside aspirin (75-325 mg daily) as part of a Dual Antiplatelet Therapy (DAPT) regimen.
Clopidogrel is not currently FDA-approved for use in pediatric patients. While it is occasionally used "off-label" by pediatric cardiologists for children with congenital heart defects or those who have undergone certain heart surgeries (such as the Fontan procedure), the safety and effectiveness have not been established through large-scale clinical trials in this population. Dosing in these rare cases is strictly determined by a specialist based on the child's weight and specific clinical needs.
No specific dosage adjustment is required for patients with kidney disease. However, because experience in patients with severe renal impairment is limited, healthcare providers will monitor these patients closely for any signs of unusual bleeding.
No dosage adjustment is typically required for mild to moderate liver disease. However, clopidogrel should be used with extreme caution in patients with severe hepatic (liver) impairment, as these individuals may have baseline bleeding tendencies or an inability to properly metabolize the drug into its active form.
Clinical trials have shown that the effectiveness and safety of clopidogrel in patients over the age of 75 are generally similar to those in younger patients. However, older adults are at a naturally higher risk for bleeding and may be taking other medications that interact with clopidogrel. No automatic dose reduction is recommended, but a careful risk-benefit analysis is necessary.
Clopidogrel should be taken exactly as prescribed by your doctor. It can be taken with or without food. To help you remember your dose, try to take it at the same time every day. The tablet should be swallowed whole with a glass of water; do not crush or chew the tablet unless specifically instructed by your doctor, as this can affect how the drug is absorbed. If you are also taking an antacid or a proton pump inhibitor (PPI), discuss the timing with your pharmacist, as some PPIs can significantly reduce the effectiveness of clopidogrel.
Store the medication at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture and heat. Keep the tablets in their original blister pack or bottle until you are ready to take them.
If you miss a dose of clopidogrel, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at once to make up for a missed one, as this significantly increases your risk of bleeding. If you miss doses for more than one day, contact your healthcare provider for guidance.
An overdose of clopidogrel can lead to life-threatening internal or external bleeding. Signs of an overdose may include excessive bruising, blood in the stool (which may look black or tarry), vomiting blood (which may look like coffee grounds), or an unusually long time for minor cuts to stop bleeding. There is no specific "antidote" that can immediately reverse clopidogrel's effects because the binding to platelets is irreversible. In an emergency setting, a platelet transfusion may be required to restore the blood's ability to clot.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking this medication without medical guidance, as stopping clopidogrel prematurely can lead to a heart attack or stroke.
Because clopidogrel is designed to prevent the blood from clotting, the most common side effects are related to bleeding and bruising.
Clopidogrel is a high-alert medication because it significantly alters the body's ability to form clots. While this is necessary to prevent heart attacks and strokes, it means that any injury or surgery becomes more dangerous. You must inform all healthcare providers, including dentists and surgeons, that you are taking clopidogrel. Most elective surgeries will require you to stop taking clopidogrel at least 5 days before the procedure to prevent excessive surgical bleeding. However, never stop taking clopidogrel without your cardiologist's explicit permission, as doing so can cause a sudden clot to form in a heart stent, leading to a massive heart attack.
As detailed in the side effects section, the FDA has issued a Boxed Warning regarding CYP2C19 Genetic Variation. This warning emphasizes that clopidogrel may not work effectively in people who are "poor metabolizers" of the drug. If you have a family history of clopidogrel "failure" (e.g., a family member who had a heart attack while taking the drug), you should discuss genetic testing with your doctor. Alternative medications like prasugrel or ticagrelor may be more effective for these individuals.
Clopidogrel must NEVER be used in the following circumstances:
In these situations, a healthcare provider must carefully weigh the risk of a blood clot against the risk of the medication:
Clopidogrel is currently classified under the older FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, clopidogrel should be used during pregnancy only if clearly needed. One specific concern is the risk of maternal hemorrhage during delivery; if a woman is taking clopidogrel, the medical team must be prepared for potential bleeding complications during a C-section or vaginal birth.
Studies in rats have shown that clopidogrel and its metabolites are excreted in milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (such as bleeding), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
As previously noted, the safety and effectiveness of clopidogrel in pediatric patients have not been established. Clinical trials in children with heart disease failed to show a significant benefit over aspirin in preventing secondary events, and the risk of bleeding remains a concern. It is not recommended for use in children under 18 unless under the strict guidance of a pediatric specialist.
Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. This binding prevents the activation of the GPIIb/IIIa receptor complex, which is the final common pathway for platelet aggregation. By blocking this pathway, clopidogrel prevents platelets from sticking to each other and to the walls of damaged blood vessels, thereby preventing the formation of an arterial thrombus.
Clopidogrel produces a dose-dependent inhibition of platelet aggregation. Statistically significant inhibition can be seen 2 hours after a single oral dose of 300 mg. With repeated daily doses of 75 mg, a steady state of 40% to 60% inhibition is usually reached within 3 to 7 days. After the drug is stopped, platelet aggregation and bleeding time gradually return to baseline values over approximately 5 days, as new platelets are produced by the bone marrow.
| Parameter | Value |
|---|---|
Common questions about Clopidogrel Bisulfate
Clopidogrel is a prescription antiplatelet medication used to reduce the risk of serious cardiovascular events like heart attacks and strokes. It is primarily prescribed to individuals who have a history of recent heart attack, recent stroke, or peripheral arterial disease. Additionally, it is a standard treatment for patients with Acute Coronary Syndrome and those who have recently received a coronary stent. By preventing platelets from clumping together, it keeps blood flowing smoothly through narrowed or stented arteries. Your doctor will determine the duration of treatment based on your specific risk factors.
The most frequently reported side effects of clopidogrel are related to increased bleeding and bruising. Patients often notice that they bruise more easily from minor impacts or that small cuts take a significantly longer time to stop bleeding. Nosebleeds and bleeding gums after dental hygiene are also common occurrences. Some individuals may experience gastrointestinal issues such as indigestion, stomach pain, or diarrhea when starting the medication. While these are common, any heavy or uncontrollable bleeding should be reported to a healthcare professional immediately.
While there is no direct chemical interaction between alcohol and clopidogrel, moderation is strongly advised. Heavy alcohol consumption can irritate the lining of the stomach, which, when combined with an antiplatelet drug, significantly increases the risk of developing stomach ulcers or gastrointestinal bleeding. Furthermore, alcohol can increase the risk of falls and physical injuries; for someone on clopidogrel, a simple fall can lead to serious internal bleeding or bruising. It is best to discuss your alcohol intake habits with your doctor to ensure your safety. Generally, an occasional drink is considered acceptable for most patients.
Clopidogrel is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. It is categorized as a drug that should be used with caution because there are no large-scale, definitive studies on its safety in pregnant women. One of the primary concerns is the increased risk of maternal bleeding during labor and delivery. If you are pregnant or planning to become pregnant, you must inform your cardiologist and obstetrician immediately. They may consider alternative therapies or create a specialized plan for managing your blood-thinning needs during childbirth.
The time it takes for clopidogrel to become effective depends on the starting dose. If you begin with a standard 75 mg daily dose, it can take between 3 to 7 days of consistent use to reach its full antiplatelet effect. However, in emergency situations like a heart attack, doctors often give a 'loading dose' of 300 mg to 600 mg. This higher dose allows the medication to begin significantly inhibiting platelets within 2 to 6 hours. Because the effect on each platelet is permanent, the protection continues as long as you take the medication daily.
No, you should never stop taking clopidogrel suddenly without your doctor's explicit instructions. Stopping the medication prematurely, especially if you have a recently placed heart stent, can lead to a sudden and life-threatening blood clot. This is known as stent thrombosis, which often results in a major heart attack or death. If you need to stop the medication for a surgery or dental procedure, your doctor will provide a specific schedule for tapering off and restarting. Always consult your cardiologist before making any changes to your antiplatelet regimen.
If you miss a dose of clopidogrel, you should take it as soon as you realize it, provided it is within the same day. If you do not remember until the following day, simply skip the missed dose and take your next regularly scheduled dose at the normal time. You should never take two doses at once to 'catch up,' as this can dangerously increase your risk of bleeding. Consistency is key to the drug's effectiveness, so using a pill organizer or phone alarm can be helpful. If you miss several doses in a row, contact your doctor for advice.
Weight gain is not a recognized or common side effect of clopidogrel based on extensive clinical trial data. If you notice a sudden or significant increase in weight while taking this medication, it is more likely related to other factors, such as changes in diet, physical activity, or other medications. In some cases, rapid weight gain can be a sign of fluid retention, which may be related to underlying heart or kidney issues rather than the clopidogrel itself. You should report any unexpected weight changes to your healthcare provider for a thorough evaluation.
Clopidogrel has several significant drug interactions that must be managed by a professional. It should not be taken with certain acid-reducing medications like omeprazole (Prilosec) or esomeprazole (Nexium), as these can make clopidogrel less effective. Combining it with other blood thinners, such as aspirin, warfarin, or NSAIDs like ibuprofen, increases the risk of bleeding. Always provide your doctor and pharmacist with a complete list of all medications, including over-the-counter drugs and herbal supplements. They can check for interactions and ensure that your combination of medicines is safe.
Yes, clopidogrel is widely available as a generic medication and is much less expensive than the original brand-name version, Plavix. Generic clopidogrel is required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. It must also prove 'bioequivalence,' meaning it works in the body the same way as the original. Most insurance plans prefer the generic version. Whether you take the brand or the generic, the clinical effects and the precautions you must follow remain the same.
Other drugs with the same active ingredient (Clopidogrel)
> Warning: Stop taking Clopidogrel and call your doctor or emergency services immediately if you experience any of the following:
The primary concern with long-term clopidogrel use is the cumulative risk of bleeding. Over years of therapy, patients may be at a higher risk for "micro-bleeds" or major bleeding events, especially if they develop other health conditions like stomach ulcers or if they begin taking other medications that affect clotting. Regular monitoring by a healthcare provider is essential to ensure that the benefit of preventing a heart attack still outweighs the risk of a major bleed.
The effectiveness of clopidogrel depends on its activation to an active metabolite by the Cytochrome P450 system, principally CYP2C19. Some individuals have genetic variations (polymorphisms) that make them "poor metabolizers" of this enzyme. In these patients, clopidogrel at standard doses forms less of the active metabolite and has a reduced effect on platelet function. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention (stenting) treated with clopidogrel at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy. Healthcare providers should consider alternative antiplatelet strategy in patients identified as CYP2C19 poor metabolizers.
Report any unusual symptoms, especially unexplained fever or bruising, to your healthcare provider immediately.
While clopidogrel does not require the frequent blood monitoring associated with drugs like warfarin, your doctor may perform the following tests:
Clopidogrel generally does not affect your ability to drive or operate heavy machinery. However, if you experience dizziness or lightheadedness as a side effect, you should avoid these activities until you know how the medication affects you.
Moderate alcohol consumption is generally not prohibited, but heavy alcohol use significantly increases the risk of stomach irritation and gastrointestinal bleeding. Alcohol can also impair your balance, increasing the risk of falls which could result in serious internal bleeding while on clopidogrel.
Discontinuing clopidogrel should only be done under strict medical supervision. There is a "rebound effect" where the risk of a blood clot (thrombosis) increases significantly in the days following discontinuation, particularly in patients with recently placed coronary stents. If you must stop the drug for surgery, your doctor will provide a specific timeline for when to stop and when to restart the medication.
> Important: Discuss all your medical conditions, especially any history of bleeding disorders or liver disease, with your healthcare provider before starting Clopidogrel.
Many herbal supplements have natural antiplatelet or anticoagulant properties and can increase the risk of bleeding when taken with clopidogrel:
Clopidogrel does not typically interfere with standard blood chemistry or urine tests. However, it will significantly affect any test of platelet function or bleeding time. If you are undergoing a "Platelet Aggregation Study," the results will be intentionally abnormal due to the medication.
For each major interaction, the primary concern is either a reduction in the drug's ability to prevent clots (leading to a heart attack) or an excessive thinning of the blood (leading to a hemorrhage). Management strategies usually involve selecting alternative medications or performing more frequent blood tests.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those bought over-the-counter.
There is a known risk of cross-reactivity among thienopyridines. If you have had a serious skin reaction or blood disorder (like TTP) while taking Ticlopidine or Prasugrel, you are at a significantly higher risk of having a similar reaction to Clopidogrel. Your doctor will likely choose a medication from a different chemical class, such as Ticagrelor, to avoid this risk.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous bleeding episodes, before prescribing Clopidogrel.
In the large CAPRIE and CURE clinical trials, approximately 35-50% of the participants were 65 years of age or older. No overall differences in effectiveness were observed between these patients and younger patients. However, the elderly are at a higher risk for bleeding due to thinner skin, more fragile blood vessels, and a higher likelihood of taking other medications (polypharmacy). In the elderly, clopidogrel should be used with caution, and fall-prevention strategies should be implemented to avoid head injuries.
Experience is limited in patients with severe renal impairment (creatinine clearance < 30 mL/min). While the drug does not appear to accumulate in the body in a way that requires dose reduction, the baseline risk of bleeding is often higher in patients with advanced kidney disease (uremic platelet dysfunction). Monitoring for hematuria (blood in the urine) is recommended.
Experience is limited in patients with severe hepatic disease who may have bleeding diatheses (a natural tendency to bleed). Clopidogrel should be used with caution in this population. In patients with mild to moderate liver disease, the conversion of the prodrug to its active form may be slightly slower, but the 75 mg dose is generally still used.
> Important: Special populations require individualized medical assessment to ensure the safest possible treatment plan.
| Protein Binding | 98% (parent drug) |
| Half-life | 6 hours (parent); 30 min (active metabolite) |
| Tmax | ~0.75 hours |
| Metabolism | Hepatic (CYP2C19, 3A4, 2B6, 1A2) |
| Excretion | Renal 50%, Fecal 46% |
Clopidogrel is classified as a thienopyridine P2Y12 receptor antagonist. It is part of the broader category of antiplatelet agents. Other drugs in this class include ticlopidine (first generation) and prasugrel (third generation). It is often compared to ticagrelor, which is also a P2Y12 inhibitor but is a cyclopentyltriazolopyrimidine and binds reversibly to the receptor.